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Background: KCNJ2/Kir2.1, a member of the classical inwardly rectifying potassium channel family, is commonly
expressed in a wide range of tissues and cell types. Previous studies indicated that Kir2.1 may be associated with
SCLC multidrug resistance (MDR). However, whether Kir2.1 can regulate MDR and its underlying mechanisms
remain poorly understood in SCLC.
Methods: KCNJ2/Kir2.1 expression was examined in tissues from fifty-two SCLC cases by immunohistochemistry.
Overexpression or knockdown of KCNJ2/Kir21 was performed in multidrug-resistant SCLC cell lines (H69AR and
H446AR) and their parental cell lines (H69 and H446) to assess its influence on cell growth, apoptosis, the cell cycle
and chemoresistance.
Results: KCNJ2/Kir2.1 was expressed in 44.23% (23/52) of SCLC tissues. Overexpression of KCNJ2/Kir2.1 was
correlated with the clinical stage and chemotherapy response in SCLC patients. Knockdown of KCNJ2/Kir2.1
expression using KCNJ2/Kir2.1 shRNA in H69AR and H446AR cells inhibited cell growth and sensitized the cancer
cells to chemotherapeutic drugs by increasing cell apoptosis and cell cycle arrest. Forced KCNJ2/Kir2.1 expression in
H69 and H446 cells promoted cell growth and enhanced multidrug resistance via reduced drug-induced apoptosis
accompanied by cell cycle arrest. KCNJ2/Kir2.1 expression was also influenced by PKC and MEK inhibitors. In
addition, multidrug resistance protein 1 (MRP1/ABCC1) was confirmed to interact with KCNJ2/Kir2.1 by Co-IP assays.
Conclusions: KCNJ2/Kir2.1 modulates cell growth and drug resistance by regulating MRP1/ABCC1 expression and is
simultaneously regulated by the Ras/MAPK pathway and miR-7. KCNJ2/Kir2.1 may be a prognostic predictor and a
potentially novel target for interfering with chemoresistance in SCLC.
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Lung cancer, with 1.35 million new cases and causing
more than 1 million deaths each year, is the most com-
mon cancer and the leading cause of cancer-related
deaths worldwide [1]. Small-cell lung cancer (SCLC), the
most aggressive type of lung cancer, constitutes approxi-
mately 15-18% of all lung cancers [2]. According to the* Correspondence: linlangg@yahoo.com
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traditionally defined by a two-stage classification system
that includes limited disease and extensive disease. At
present, chemotherapy remains the first treatment op-
tion for SCLC patients. Although 80-90% of SCLC pa-
tients are initially responsive to chemotherapy, most of
them succumb to the disease within a year due to rap-
idly developing multidrug resistance (MDR) [3,4]. Thus,
MDR has become the main obstacle to the treatment of
SCLC and a central issue in improving its prognosis.
Kir2.1, encoded by the KCNJ2 gene, is a member of
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current in a wide range of tissues and cell types, including
neurons, skeletal muscle, cardiac myocytes, and immune
system and carcinoma cells [5]. The KCNJ2 gene was first
cloned by Kubo et al. from a macrophage cell line in 1993
[6]. Similar to the other members of the Kir family, Kir2.1
is tetrameric, containing two transmembrane helix do-
mains (M1 and M2), an ion-selective P-loop between M1
and M2, and cytoplasmic N- and C-terminal domains.
Functionally, Kir2.1 plays a key role in maintaining the
resting membrane potential and regulating cellular excit-
ability in SCLC cells, cardiac myocytes, skeletal muscle
and neurons [7-9]. Changes in the expression levels of K+
channels induced by aberrant KCNJ2 expression have sub-
stantial effects on cellular processes such as cell death,
apoptosis, proliferation and adhesion, which is linked to a
variety of cardiac and neurological disorders [10-15]. Hu-
man SCLC cells are suggested to be of neurorctodermal
origin and exhibit electrophysiological characteristics typ-
ical of neuroendocrine cells. Previous studies have indi-
cated that the large, inwardly rectifying K+ current is
generated by Kir2.1 and may be associated with SCLC cell
MDR [16,17]. However, whether Kir2.1 can regulate MDR
and its underlying mechanisms remain poorly understood
in SCLC.
MicroRNAs (miRNAs) are a class of small, non-coding
RNAs of 18–24 nucleotides in length that negatively
regulate the expression of specific genes by binding to
the 3′ untranslated region (3’UTR) of an mRNA, leading
to either translational inhibition or mRNA degradation
[18]. Recent evidence has shown that more than 50% of
miRNAs are located in cancer-associated genomic break
points and can function as tumor suppressor genes or
oncogenes depending on their targets [19,20]. Moreover,
extensive studies have indicated that miRNAs are closely
related to responses to chemotherapeutic treatment
[21-24]. For example, Yang et al. reported that miR-214
induced cell survival and cisplatin resistance in ovarian
cancer [25]. Additionally, miR-650 levels affected the
chemosensitivity of lung adenocarcinoma cells to doce-
taxel via Bcl-2/Bax expression regulation by directly
targeting ING4 [23], and suppression of miR-137 ex-
pression in a drug-resistant SCLC cell line increased its
sensitivity to cisplatin [26]. Moreover, our previous
miRNA expression profile study revealed that the ex-
pression of 61/852 miRNAs was significantly increased
(>3-fold) in MDR SCLC H69AR cells compared with
their drug-sensitive parental cell line H69, suggesting a
role for these differentially expressed miRNAs in the
development of drug resistance in SCLC cells [22].
We previously found that KCNJ2 is overexpressed in
H69AR cells compared to parental H69 cells, whereas
miR-7 is expressed at a lower level in H69AR cells com-
pared with H69 cells (unpublished data). In the presentstudy, we further investigated the roles of KCNJ2/Kir2.1
in drug resistance using human drug-resistant SCLC
cell lines (H69AR and H446AR). The correlation be-
tween KCNJ2 expression and clinical drug response
was analyzed in SCLC patients. We then validated the
interaction between Kir2.1 and MRP1/ABCC1 by co-
immunoprecipitation (Co-IP). Furthermore, we showed
that KCNJ2 was modulated by the Ras/MAPK pathway
and directly targeted by miR-7. Collectively, our results
provide a novel explanation for the chemoresistance of
SCLC and suggest that KCNJ2/Kir2.1 plays a crucial
role in SCLC MDR.
Results
Kir2.1 expression is associated with the clinical stage and
the chemotherapy Response of SCLC patients
To investigate the clinical features of Kir2.1 expression
in SCLC, we first examined the expression levels of
Kir2.1 in 52 SCLC specimens and 15 normal lung tissues
by immunohistochemistry (IHC). Kir2.1 was localized on
the membrane of the cancer cells (Figure 1A), whereas
no positive Kir2.1 staining was observed in normal lung
alveolar epithelium (Figure 1B). And the corresponding
IHC staining scores are indicated in Additional file 1A:
Figure S1A. Additionally, the positive expression of
Kir2.1 was 23 of 52 (44%) in SCLC and 1 of 15 in nor-
mal bronchial epithelium, respectively (Figure 1E).
We further analyzed the correlation between Kir2.1
expression and the clinicopathological features of SCLC
patients. As shown in Table 1, Kir2.1 expression was sig-
nificantly more frequent at the extensive disease stage
and in the drug-resistant group than at the limited dis-
ease stage and in the drug-sensitive group. Correlation
analysis showed that Kir2.1 expression was significantly
associated with clinical stage and chemotherapy re-
sponse in SCLC patients (P < 0.05), but not with gender,
age or smoking history (P > 0.05) (Table 1).
KCNJ2/Kir2.1 expression is correlated with
chemoresistance in SCLC
Our previous study indicated a 4.75-fold upregulation of
KCNJ2 expression in H69AR cells compared with their
parental H69 cells by cDNA microarray analysis (unpub-
lished data). We confirmed the result in two pairs of
SCLC cells (H69AR/H69 and H446AR/H446) by qRT-
PCR, western blotting and immunofluorescence assays.
Figure 2 shows that KCNJ2/Kir2.1 expression was sig-
nificantly increased at both mRNA and protein levels in
H69AR and H446AR cells as compared with H69 and
H446 cells, respectively.
Based on the upregulation of KCNJ2/Kir2.1 in MDR
SCLC cells, we hypothesized that KCNJ2/Kir2.1 may be
involved in SCLC chemoresistance. To test this hypoth-
esis, we performed gain-of-function and loss-of-function
Figure 1 Kir2.1 and MRP1/ABCC1 expression in SCLC and normal alveolar epithelium tissues by IHC. (A-B) Representative images of Kir2.1 IHC
staining in SCLC (A) and normal alveolar epithelium tissues (B). (C-D) Representative images of MRP1/ABCC1 IHC staining in SCLC (C) and normal
alveolar epithelium tissues (D). Brown chromogen represents positive staining. Scale bar, 50 μm. (E) The IHC staining results of Kir2.1 and MRP1/ABCC1
expression in normal alveolar epithelium and SCLC tissues. The positive rate of Kir2.1 and MRP1/ABCC1 were higher in SCLC tissues than
normal alveolar epithelium. **, P < 0.01 compared with normal alveolar epithelium.
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overexpressing sublines, H69-KCNJ2 and H446-KCNJ2,
by transfecting H69 and H446 cells with pcDNA3.1-
KCNJ2, and their corresponding negative control sub-
lines (H46-NC and H446-NC) that were transfected
with pcDNA3.1 empty vector. qRT-PCR and western
blotting analyses showed that KCNJ2/Kir2.1 expression
was significantly upregulated at both the mRNA and pro-
tein levels in H69-KCNJ2 and H446-KCNJ2 as compared
with H46-NC and H446-NC, respectively (Figure 3).
Subsequently, we stably transfected multidrug-resistant
H69AR and H446AR cells with two shRNAs (shKCNJ2-1
and shKCNJ2-2) targeting KCNJ2 to inhibit KCNJ2/Kir2.1
expression. As shown in Figure 3, KCNJ2/Kir2.1 expres-
sion was notably decreased in cells transfected withshKCNJ2-1 or shKCNJ2-2 (H69AR-shKCNJ2-1, H69AR-
shKCNJ2-2, H446AR-shKCNJ2-1 and H446AR-shKCNJ2-
2) when compared with their corresponding negative
controls, H69AR-shNC or H446AR-shNC. The viability
and sensitivity of the SCLC cells to chemotherapeutic
drugs (ADM, CDDP and VP-16) were then assessed using
CCK8 assays. Table 2 shows that the IC50 values of H69
and H446 cells significantly increased after transfection
with pcDNA3.1-KCNJ2, whereas the IC50 values of H69AR
and H446AR cells decreased after the introduction of
shKCNJ2-1 or shKCNJ2-2. Collectively, these results indi-
cated that KCNJ2/Kir2.1upregulation or downregulation
could significantly affect the sensitivity of SCLC cells to
chemotherapeutic drugs, suggesting that KCNJ2/Kir2.1 ex-
pression may be associated with chemoresistance in SCLC.




n Expression of Kir2.1 Expression of MRP1/ABCC1
+ - P + - P
Gender 1 1
Male 43 18 25 21 22
Female 9 5 4 6 3
Age 0.892 0.426
<55† 23 7 16 10 13
≥55 29 16 13 17 12
Smoking history 1 0.328
Yes 41 20 21 22 19
No 11 3 8 5 6
Clinical stage 0.032 0.001
limited disease 25 7 18 6 19
extensive disease 27 16 11 21 6
Chemotherapy reponse 0.021 0.001
Sensitive group 25 6 19 7 18
Resistant group 22 17 5 20 2
†median age.
-, negative expression; +, positive expression.
The P-value was calculated by χ2 test.
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following exposure to chemotherapeutic drugs
The above observations prompted us to investigate the
possible mechanisms of KCNJ2/Kir2.1 in SCLC chemore-
sistance. Using flow cytometry analysis, we evaluated the
effect of KCNJ2/Kir2.1 on cell cycle control and apoptosis
following exposure to chemotherapeutic drugs.
As shown in Figure 4, overexpression of KCNJ2/
Kir2.1 in H69 and H446 cells induced an increase of
cells entering the G0/G1 phase and a corresponding de-
cline of cells in the S phase after treatment with ADM
(4.6 μM) for 24 h. In contrast, knockdown of KCNJ2/
Kir2.1 by shKCNJ2-1 or shKCNJ2-2 in H69AR and
H446AR cells resulted in a significant decrease of cells
in the G0/G1 phase and an increase of cells in the S
phase. These results suggest that KCNJ2/Kir2.1could
induce cell cycle arrest.
We further examined the impact of KCNJ2/Kir2.1 on
apoptosis. Notably, after treatment with ADM (4.6 μM)
for 24 h, upregulating KCNJ2/Kir2.1 expression in H69
and H446 cells prevented drug-induced apoptosis. Mean-
while, silencing KCNJ2/Kir2.1 expression in H69AR and
H446AR cells significantly increased drug-induced
apoptosis (Figure 5). In addition, similar results of cell
cycle and apoptosis analysis were observed in SCLC
cells after treatment with CDDP (16.7 μM) or VP-16
(34 μM) (Additional file 2: Figure S2, Additional file 3:
Figure S3, Additional file 4: Figure S4, and Additional
file 5: Figure S5).KCNJ2/Kir2.1 enhances SCLC tumor growth in vivo
To further determine the effect of KCNJ2/Kir2.1 on
tumor growth in vivo, SCLC cells with altered KCNJ2/
Kir2.1 expression were subcutaneously injected into
nude mice. As shown in Figure 6A-D, the injection of
KCNJ2/Kir2.1-overexpressing H69 and H446 cells resulted
in significantly increased tumor weights compared with the
injection of the corresponding NC cells. However, with
KCNJ2/Kir2.1-knockdown H69AR and H446AR cells, the
average tumor weight decreased to 12-25% of that of the
tumors originating from the cells transfected with shNC.
Additionally, the injection of KCNJ2/Kir2.1-overexpressing
H69 and H446 cells resulted in earlier tumor formation
compared with the injection of NC cells. In contrast, the
time until tumor appearance was prolonged in H69AR and
H446AR cells transfected with shKCNJ2-1 or shKCNJ2-2
compared with that transfected with shNC. These findings
demonstrated that KCNJ2/Kir2.1 enhanced SCLC tumor
growth in vivo.
We then further examined Kir2.1 expression in SCLC
tissues from the tumor xenografts by IHC. The results
showed higher Kir2.1 expression in H69-KCNJ2 tumors
and lower expression in shKCNJ2-1 H69AR tumors as
compared with the corresponding NC cells (Figure 6E
and Additional file 1B: Figure S1B). Moreover, evaluated
by staining scores, Kir2.1 and MRP1/ABCC1 expression
were significantly upregulated in tumors originating
from H69 and H446 cells transfected with KCNJ2-
overexpressing vector and downregulated in tumors of
Figure 2 KCNJ2/Kir2.1 expressionin SCLC cells. (A) KCNJ2 mRNA level was determined by qRT-PCR in SCLC multi-drug resistant H69AR and
H446AR cells and their corresponding parental cells, H69 and H446. (B-C) Western blotting and immunofluorescence analyses showed that
Kir2.1expression was upregulatedin H69ARand H44AR cellsas compared with H69 and H446 cells, respectively. Values of three independent
experiments are represented as the mean ± SD. **, P < 0.01 compared with the parental cells.
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or shKCNJ2-2 (Figure 6F).
KCNJ2/Kir2.1 interacts with MRP1/ABCC1
We previously found that the expression of both KCNJ2/
Kir2.1 and MRP1/ABCC1 was increased in H69AR cells
compared with parental H69 cells by cDNA microarray
analysis [22]. To further investigate the relationship be-
tween KCNJ2/Kir2.1 and MRP1/ABCC1 in SCLC, wesimultaneously detected the expression of these two pro-
teins in SCLC and normal lung tissues by IHC. Membrane
localization of KCNJ2/Kir2.1 and MRP1/ABCC1 was ob-
served in cancer cells (Figure 1A and C), whereas no posi-
tive MRP1/ABCC1 staining was observed in normal lung
alveolar epithelium (Figure 1D). Similar to Kir2.1, the rate
of MRP1/ABCC1 positivity was much higher in SCLC
specimens (52%) than in normal bronchial epithelium
(7%) (Figure 1E). Correlation analysis showed that MRP1/
Figure 3 Altered KCNJ2/Kir2.1 expression in SCLC cells. qRT-PCR (A) and Western blot (B) analyses showed forced KCNJ2/Kir2.1 expression in
H69 and H446 cells after transfection of pcDNA3.1-KCNJ2, and KCNJ2/Kir2.1 inhibition in H69AR and H446AR cells by shKCNJ2-1or shKCNJ2-2. The
bars represent the means ± SD of three independent experiments. **, P < 0.01 compared withthe corresponding NC cells transfected with pcDNA3.1
empty vector or shNC.
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SCLC patient’s clinical stage and chemotherapy response,
but not with gender, smoking, age or lymph node metasta-
sis (Table 1). Furthermore, as shown in Table 3, MRP1/
ABCC1 expression was clearly correlated with Kir2.1 ex-
pression in SCLC tissues.
To explore the relationship between KCNJ2/Kir2.1 and
MRP1/ABCC1, we analyzed MRP1/ABCC1 expression
changes with upregulated or downregulated KCNJ2/Kir2.1
expression. qRT-PCR and western blotting analyses re-
vealed a marked increase in MRP1/ABCC1 in H69 and
H446 cells transfected with pcDNA3.1-KCNJ2 and a de-
crease in MRP1/ABCC1in H69AR and H446AR cells
transfected with shKCNJ2-1 or shKCNJ2-2 (Figure 7A-B).
These results provide evidence indicating that KCNJ2/
Kir2.1 could affect MRP1/ABCC1 expression.
We performed Co-IP assays to further evaluate the
interaction between KCNJ2/Kir2.1 and MRP1/ABCC1
in SCLC cells. Cell lysates from H69 cells were pre-
pared and immunoprecipitated with an anti-Kir2.1antibody. Both immunoprecipitates and cell lysates
without IP were blotted with anti-ABCC1 and anti-
Kir2.1. As shown in Figure 7C, Kir2.1 formed a com-
plex with ABCC1. These data reveal that Kir2.1 can
interact with MRP1/ABCC1.
The modulatory effect of the Ras/MAPK pathway on
KCNJ2/Kir2.1
Based on previous findings that the Ras-MAPK pathway
is involved in modulating the inward rectifier potassium
channel IRK1 [5], we investigated whether the Ras-
MAPK pathway could regulate KCNJ2/Kir2.1 in SCLC.
Initially, SCLC MDR H69AR and H446AR cells were
treated with PKC inhibitor (staurosporine, 10 nM) and
MEK inhibitor (U0126, 10 μM) to inhibit two key com-
ponents of Ras-MAPK pathway respectively. Then, we
examined the mRNA and protein levels of both KCNJ2/
Kir2.1 and MRP1/ABCC1 in these SCLC cells by qRT-
PCR and Western blotting. The results showed that the
expression of both KCNJ2/Kir2.1 and MRP1/ABCC1
Table 2 Effect of KCNJ2/Kir2.1 on drug sensitivity
(X ± s, n=3, μg/ml)
Cells IC50
ADM CDDP VP-16
H69 5.222 ± 0.117 17.711 ± 0.279 124.03 ± 2.791
H69-NC 5.426 ± 0.87 17.548 ± 0.423 122.27 ± 2.938
H69-KCNJ2 13.678 ± 0.195* 22.649 ± 7.623* 283.41 ± 6.884*
H446 4.293 ± 0.049 4.529 ± 0.063 52.342 ± 3.0
H446-NC 4.412 ± 0.212 4.884 ± 0.068 50.296 ± 1.53
H446-KCNJ2 14.048 ± 0.242* 15.303 ± 0.712* 80.064 ± 4.97*
H69AR 211.06 ± 6.665 76.652 ± 1.238 531.58 ± 6.06
H69AR-shNC 209.69 ± 3.157 77.32 ± 1.362 529.72 ± 4.704
H69AR-shKCNJ2-1 62.275 ± 1.214* 44.583 ± 1.514* 394.74 ± 19.996*
H69AR-shKCNJ2-2 18.823 ± 0.935* 33.183 ± 2.637* 359.51 ± 8.62*
H446AR 39.29 ± 0.738 133.73 ± 4.875 179.63 ± 2.978
H446AR-shNC 42.35 ± 1.388 132.12 ± 4.434 175.64 ± 8.726
H446AR-shKCNJ2-1 27.082 ± 2.289* 72.724 ± 0.896* 118.31 ± 4.934*
H446AR-shKCNJ2-2 19.920 ± 0.688* 21.517 ± 2.693* 108.51 ± 5.772*
*P < 0.05 (compared with corresponding negative control groups).
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with staurosporine and U0126 as compared with the
controls (Figure 8). Moreover, an additive inhibitory ef-
fect on KCNJ2/Kir2.1 and MRP1/ABCC1 expression was
observed in SCLC cells upon simultaneous PCK and
MEK suppression (Figure 8). These findings suggest that
KCNJ2/Kir2.1 modulation is mediated by the Ras-PKC-
MAPK pathway.MiR-7 directly regulates KCNJ2 expression in SCLC
All processes involved in cancer, including apoptosis and
proliferation, have been shown to be regulated by small
regulatory non-coding RNAs, i.e., miRNAs [27]. There-
fore, the above results showing that KCNJ2/Kir2.1 is
overexpressed in SCLC led us to hypothesize that
KCNJ2/Kir2.1 expression may be regulated by endogen-
ous miRNAs. We utilized three prediction algorithms
(PicTar, TarScan and miRBase database) to predict the
miRNAs that possibly target KCNJ2 in SCLC. The re-
sults showed that miR-7, miR-212 and miR-1 have po-
tential interaction sites in the 3’-untranslated region
(3’UTR) of KCNJ2 mRNA. Based on the involvement of
miR-7 in drug resistance, we investigated whether
KCNJ2 is regulated by miR-7. We transfected an miR-7
agomir or antagomir into SCLC cells to increase or de-
crease miR-7 expression, respectively (Figure 9A). The
levels of KCNJ2/Kir2.1 and MRP1/ABCC1 were then
measured by qRT-PCR and Western blotting at 48 h
post-transfection. The expression of both KCNJ2/Kir2.1and MRP1/ABCC1 decreased significantly after transfec-
tion of miR-7 agomir compared with NC agomir, whereas
the miR-7 antagomir clearly upregulated the levels of
KCNJ2/Kir2.1 and MRP1/ABCC1 when compared with
NC antagomir (Figure 9B-D).
To test whether miR-7 can regulate KCNJ2/Kir2.1
via direct interaction with the KCNJ2 3’UTR, we
constructed luciferase reporter vectors containing wild-
type (psiCHECK2-KCNJ2-wt) or mutated (psiCHECK2-
KCNJ2-mt) 3’UTRs of KCNJ2mRNA. H69 cells were
cotransfected with each vector and either the miR-7
agomir or antagomir or the corresponding NC; the
KCNJ2 luciferase activity was measured after cotrans-
fection. As shown in Figure 9E, the miR-7 agomir sup-
pressed luciferase activity when cotransfected with the
wildtype reporter vector as compared with NC agomir,
whereas the miR-7 antagomir increased luciferase activ-
ity compared with NC antagomir. In contrast, the lucif-
erase activity of the mutated reporter vector was not
affected by simultaneous transfection with the miR-7
agomir or antagomir (Figure 9E). Taken together, these
findings suggest that KCNJ2 is a direct target of miR-7
in SCLC.
Regulation of chemoresistance by KCNJ2/Kir2.1 is partly
mediated by miR-7
To further investigate the effect of miR-7 on the chemore-
sistance of SCLC cells, we analyzed the sensitivity of SCLC
cells to chemotherapeutic drugs (ADM, CDDP and VP-16)
after transfection with the miR-7 agomir, antagomir or the
corresponding NC. The IC50 values of the chemotherapeu-
tic drugs were significantly decreased after miR-7 agomir
transfection compared with the controls. Meanwhile, the
IC50 values increased when expression of miR-7 was sup-
pressed by miR-7 antagomir (Figure 10). These results
demonstrated that the upregulation of miR-7 expression
sensitized the SCLC cells to all three chemotherapeutic
drugs, whereas the downregulation of miR-7 desensitized
the SCLC cells. Together, these data suggest that miR-7 de-
regulation may be responsible for the effects of KCNJ2 on
SCLC chemoresistance.
miR-7 expression is associated with Kir2.1 levels and
prognosis in SCLC patients
To further confirm the association between miR-7 and
KCNJ2/Kir2.1 expression, we analyzed miR-7 expression
in the above-mentioned 52 SCLC tissue specimens by
qRT-PCR. The median value of miR-7 expression was
chosen as the cut-off point for separating SCLC tissues
with low-level miR-7 expression (n = 26) from those
with high-level miR-7 expression (n = 26). Correlation
analysis showed that miR-7 expression was inversely cor-
related with KCNJ2/kir2.1 (P < 0.001) and MRP1/ABCC1
expression (P = 0.002) (Table 4). Moreover, low-level
Figure 4 KCNJ2/Kir2.1 affects the cell cycle distribution of SCLC cells after ADM treatment. (A) Representative FACS profiles are shown. The
numbers indicate the percentages of cells in the G0/G1, S and G2/M phases. (B) Histographs for the cell cycle distribution of SCLC cells. H69 and H446
cells stably transfected with KCNJ2 expression plasmid (H69-KCNJ2 and H446-KCNJ2) showed an increased proportion in the G0/G1 phase and a decreased
proportion in the S phase when compared with H69-NC and H446-NC, respectively. KCNJ2/Kir2.1-knockdown cells (H69AR-shKCNJ2-1, H69AR-shKCNJ2-2,
H446AR-shKCNJ2-1 and H446AR-shKCNJ2-2) showed a decreased proportion in the G0/G1 phase and an increased proportion in the S phase
when compared with H69AR-shNC or H446AR-shNC. Data are shown as the means ± SD from three independent experiments. *, P < 0.05;
**, P < 0.01 compared with the corresponding NC cells transfected with pcDNA3.1 empty vector or shNC.
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aggressive clinical stage (P = 0.012) (Table 4). Kaplan-
Meier analysis revealed that SCLC patients with low miR-
7 expression had much shorter overall survival times thanpatients with high miR-7 expression (Additional file 6:
Figure S6). In addition, miR-7 expression reached sig-
nificance in a univariate Cox proportional hazards re-
gression model (P = 0.024, Additional file 7: Table S1).
Figure 5 (See legend on next page.)
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Figure 5 KCNJ2/Kir2.1 affects cell apoptosis in SCLC cells after ADM treatment. (A) Cells were analyzed by annexin-V/propidium iodide (PI) dual
labeling. Representative FACS profiles are shown, on which cell population in the quadrant of Annexin V+PI−represents apoptotic cells. (B) Histographs
for cell apoptosis of SCLC cells. The percentage of the Annexin V+PI−cell population was determined. The results show data from at least three
independent experiments. **, P < 0.01 compared with the corresponding NC cells.
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Previous studies have revealed that K+ channel
blockers inhibit SCLC cell proliferation via membrane
depolarization [16,28] and that some types of inwardly
rectifying K+channels are involved in SCLC MDR
[16,29]. In our previous analysis of a cDNA microarray
[22], KCNJ2 expression was increased in SCLC multi-
drug resistant H69AR cells compared with the parent
H69 cell line, suggesting that KCNJ2/Kir2.1 might be
relevant in the drug resistance of SCLC. However, the
molecular mechanism by which KCNJ2/Kir2.1 exerts aFigure 6 KCNJ2/Kir2.1 enhances SCLC tumor growth in vivo. (A, C) Tu
and H69AR cells with altered KCNJ2 expression.1, H69; 2, H69-NC; 3, H69-KC
(B, D) Tumors formation and growth curves of tumor volumes formed by H4
3, H446-KCNJ2; 4, H446AR; 5, H446AR-NC; 6, H446AR-shKCNJ2-1; 7, H446A
xenografts originating from H69-NC, H69-KCNJ2, H69AR-NC and H69AR-shKCN
represents positive staining. Scale bar, 50 μm. (F) Kir2.1 and MRP1/ABCC1expr
0.05 compared with the corresponding NC cells transfected with pcDNA3.1 erole in the chemoresistance of SCLC was not clear
until now. In this study, we showed that the mRNA
and protein expression of KCNJ2/Kir2.1 was upregu-
lated in both H69AR and H446AR cells compared with
that in their respective parental cells, confirming the re-
sults of the SCLC mRNA expression profiling. Moreover,
Kir2.1 expression in 52 clinical SCLC tissues was signifi-
cantly associated with the chemotherapeutic responses of
the SCLC patients. To further investigate whether KCNJ2/
Kir2.1 regulates MDR, we first established two stable
KCNJ2/Kir2.1-overexpressing sublines, H69-KCNJ2 andmors formation and growth curves of tumor volumes formed by H69
NJ2; 4, H69AR; 5, H69AR-NC; 6, H69AR-shKCNJ2-1; 7, H69AR-shKCNJ2-2.
46 and H446AR cells with altered KCNJ2 expression. 1, H446; 2, H446-NC;
R-shKCNJ2-2. (E) Kir2.1 expression was examined by IHC in the tumor
J2-1 cells. Representative images were shown. Brown chromogen
ession were evaluated by staining scores in the tumor xenografts. *, P <
mpty vector or shNC.
Table 3 The correlation between Kir2.1 and MRP/ABCC1
in SCLC tissues
ABCC1 Kir2.1 χ2 P
- +
- 23 2 25.622 <0.001
+ 6 21
-, negative expression; +, positive expression.
The P-value was calculated by χ2 test.
Figure 7 Kir2.1 interacts with MRP1/ABCC1 expression. (A-B) qRT-PCR (A)
or downregulation successfully elevated or suppressed MRP1/ABCC1 mRNA an
MRP1/ABCC1 was analyzed by Co-IP. Anti-Kir2.1 antibody was used for IP. The
Western blotting with the indicated specific antibodies.
Liu et al. Molecular Cancer  (2015) 14:59 Page 11 of 19H446-KCNJ2, and suppressed KCNJ2/Kir2.1 expression in
H69AR and H446AR cells by shRNAs specifically target-
ing KCNJ2. Next, we examined the effect of KCNJ2/Kir2.1
upregulation and downregulation on the sensitivity of
SCLC cells to chemotherapeutic drugs (ADM, CDDP
and VP-16). H69AR and H446AR cells became much
more sensitive to chemotherapeutic agents than the NC
groups after significantly inhibiting KCNJ2/Kir2.1 ex-
pression, whereas KCNJ2/Kir2.1 upregulation led to the
desensitization of H69 and H446 cells to these drugs.and Western blotting (B) analyses showed that KCNJ2/Kir2.1 upregulation
d protein levels, respectively. (C) The interaction between Kir2.1 and
amounts of ABCC1 and Kir2.1 in the immunoprecipitates were detected by
Figure 8 The Ras/MAPK pathway modulates the expression of KCNJ2/Kir2.1. (A-B) qRT-PCR and Western blot analyses showed that KCNJ2/
Kir2.1 expression was inhibited at the mRNA and protein levels in H69AR and H446AR cells treated with the PKC inhibitor staurosporine, the MEK
inhibitor U0126, or staurosporine plus U0126. *, P < 0.05 compared with the corresponding mock cells.
Liu et al. Molecular Cancer  (2015) 14:59 Page 12 of 19Our findings indicate that KCNJ2/Kir2.1 is closely cor-
related with chemoresistance and may represent a poten-
tial clinical strategy for interfering with chemoresistance
in SCLC; however, more clinical data are needed to verify
this proposal.
To further investigate the possible mechanism of
KCNJ2/Kir2.1 in SCLC chemoresistance, we evaluated
the effect of KCNJ2/Kir2.1 on apoptosis and cell cycle
control by flow cytometry. Our results indicated that
one reason for the resistant phenotype of MDR SCLC
cells may be that KCNJ2/Kir2.1 induces cell cycle arrest
at the G0/G1 phase and inhibits drug-induced apoptosis.
Moreover, consistent with the results obtained in vitro,
KCNJ2/Kir2.1 promoted tumor growth in a xenograft
nude mouse model. These results suggest that KCNJ2/
Kir2.1 may play an oncogenic role in SCLC.
In addition to the potential therapeutic impact of
KCNJ2/Kir2.1, our studies shed light on the mechanisms
by which KCNJ2/Kir2.1 mediates MDR in SCLC. Several
studies have confirmed that MRP1/ABCC1 is highly
expressed in H69AR cells [30,31], and may be closely re-
lated to chemoresistance in SCLC [22]. Enyeart et al.
showed that K+ channels, including KCNJ2/Kir2.1, might
function with MRP1/ABCC1 [32]. In this study, we first
found that MRP1/ABCC1 expression was positively cor-
related with KCNJ2/Kir2.1in SCLC cells and tissues. To
further confirm this relationship, we performed Co-IP
and demonstrated that Kir2.1 can interact with MRP1/ABCC1 in H69AR cells. Our data suggest that KCNJ2/
Kir2.1 might affect the resistance to chemotherapy via
interaction with MRP1/ABCC1 in SCLC cells.
The KCNJ2/Kir2.1 channel is modulated by several
factors, including PKC, direct tyrosine kinase phosphoryl-
ation, the acidic intracellular pH and AMP-activated pro-
tein kinase [17,33-35]. The work reported by Giovannardi
et al. has shown that RAS-PKC-MEK signaling is also an
important regulator of KCNJ2/Kir2.1 [5]. In this study,
KCNJ2/Kir2.1 expression at the mRNA and protein levels
was markedly downregulated in the H69AR and H446AR
cells after treatment with staurosporine, a PKC inhibitor,
or U0126, a MEK inhibitor. It has been suggested that the
KCNJ2/Kir2.1 channel is regulated by the Ras-MAPK
pathway. However, whether Ras-MAPK signaling is in-
volved in the mechanism by which KCNJ2/Kir2.1regulates
SCLC MDR remains unknown.
miRNAs play an important role in the development of
drug resistance in some tumor types [24,36], and our
previous study showed that some miRNAs are involved
in the development of drug resistance in SCLC cells
[22]. Thus, we hypothesized that certain miRNAs could
affect chemosensitivity by directly targeting KCNJ2/
Kir2.1 in SCLC, and we identified miR-7 as a direct sup-
pressor of KCNJ2/Kir2.1. Recently, miR-7 was reported
to be a tumor suppressor due to its abilities to suppress
cell growth and metastasis [37-39], promote apoptosis
and inhibit drug resistance [40]. Our data showed that
Figure 9 KCNJ2 is a direct target of miR-7. (A) The miR-7levels in H69, H69AR, H446, H446AR cells were measured after transfection with an
miR-7 agomir or antagomir or the corresponding NC. (B-D) KCNJ2/Kir2.1 and MRP1/ABCC1expression at mRNA and protein levels was assessed
after transfection of SCLC cells with an miR-7 agomir or antagomir or the corresponding NC. (E) A dual luciferase assay was performed in H69
cells transfected with the luciferase construct alone or cotransfected with anmiR-7 agomir or antagomir or the corresponding NC. *, P < 0.05;
**, P < 0.01 compared with the corresponding NC cells transfected with NC agomir or NC antagomir.
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Figure 10 The effect of miR-7 on drug sensitivity. (A-B) The sensitivity of H69 and H69AR cells to chemotherapeutic drugs (ADM, CDDP and VP-16)
after transfected with the miR-7 agomir, antagomir or the corresponding NC. (C-D) The sensitivity of H446 and H446AR cells to chemotherapeutic
drugs (ADM, CDDP and VP-16) after transfected with the miR-7 agomir, antagomir or the corresponding NC. ADM, Adriamycin; CDDP, Cisplatin; VP-16,
Etoposide. *P < 0.05 (compared with corresponding negative control groups).
Liu et al. Molecular Cancer  (2015) 14:59 Page 14 of 19an miR-7 agomir or an antagomir led to a significant de-
crease or increase, respectively, in KCNJ2/Kir2.1 expres-
sion at both the mRNA and protein levels in SCLC cells.
Luciferase reporter assays demonstrated that miR-7 dir-
ectly targeted KCNJ2 in H69AR cells, and miR-7 expres-
sion was associated with SCLC chemoresistance. In
addition, we found that miR-7 downregulation wasTable 4 Relationship between miR-7 expression and clinicopa









Limited disease 25 8
Extensive disease 27 18
Drug-sensitivity
Sensitive group 25 10








-, low expression; +, high expression.
The P-value was calculated by χ2 test.associated with KCNJ2/Kir2.1 expression and advanced
clinicopathological features of SCLC tissues. These find-
ings indicate that KCNJ2/Kir2.1 is directly regulated by
miR-7 in SCLC.
In summary, our findings reported here provide a
novel mechanism by which KCNJ2/Kir2.1 modulates the
sensitivity of SCLC cells to chemotherapeutic drugs,thological characteristics in SCLC patients
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simultaneous regulation by the Ras/MAPK pathway and
miR-7. Therefore, our study indicates that KCNJ2/Kir2.1




Fifty-two SCLC patient tissue samples were obtained from
Zhujiang (Southern Medical University, Guangzhou, China)
and Wujing Hospitals (Guangzhou Medical University,
Guangzhou, China). All samples were confirmed as SCLC
by pathologic examination and were further distinguished
as limited disease (25 cases) or extensive disease (27 cases)
according to the Veterans Administration Lung Study
Group. All patients gave informed consent prior to the
collection of specimens according to the institutional
guidelines. Tissue samples were snap-frozen in the op-
erating room immediately after surgery, and non-tumor
tissues were sent to the pathology department for diag-
nosis by a board-certified pathologist. The non-tumor
tissues (pericarcinomatous tissues) were confirmed to
have surrounded the tumor tissue and to be free of can-
cer cells. A paraffin-embedded tissue specimen was
available for each included patient. Under the protocol
approved by the Institutional Review Board, informed
consent was obtained from the patients or their
guardians.
Cells culture and transfection
Human SCLC H69 and H446 cell lines and the drug-
resistant H69ARsubline were purchased from American
Type Culture Collection (ATCC, USA). The other drug-
resistant subline, H446AR, was established in our la-
boratory by culturing H446 cells in adriamycin (ADM).
These cell lines were maintained in RPMI 1640 (GIBCO,
Mississauga, Canada) supplemented with 10% heat-
inactivated calf serum (HyClone, Logan, UT) and L-
glutamine (Beyotime, Jiangsu, China) in an incubator at
37°C with 5% CO2. The H69AR and H446AR cell lines
were challenged monthly for maintained resistance to
the selected drugs, and their growth and morphology
were monitored. The drug-resistant cells were main-
tained in drug-free medium for at least 2 weeks before
any experiment.
For transient miRNAtransfection, cells were placed in
standard media without antibiotics for 24 h before being
transfected with anmiR-7agomir or antagomir or the cor-
responding negative controls (GenePharma, Shanghai,
China) using Lipofectamine 2000 and OPTI-MEMI (Invi-
trogen) according to the manufacturer’s protocol. For
stable transfections, the KCNJ2 coding region was inserted
into pcDNA3.1 (GenePharma) andtransfected into H69
and H446 cells to stably overexpress KCNJ2 (H69-KCNJ2and H446-KCNJ2). Cells stably transfected with the
pcDNA3.1 empty expression vector (Invitrogen) were
used as their corresponding negative controls (H69-NC
and H446-NC). Positive transfectants were selected
with 800 μg/ml geneticin (G418; Invitrogen). The
KCNJ2 gene was knocked down using two different
KCNJ2 short-hairpin RNAs (shKCNJ2-1, shKCNJ2-2),
which were obtained from GenePharma and transfected
into H69AR and H446AR cells (H69AR-shKCNJ2-1,
H69AR-shKCNJ2-2, H446AR-shKCNJ2-1 and H446AR-
shKCNJ2-2) using Lipofectamine 2000. A negative con-
trol shRNA (shNC) was transfected into H69AR and
H446AR cells (H69AR-shNC and H446AR-shNC) as
the corresponding negative controls for cells transfected
with shKCNJ2-1 or shKCNJ2-2. After the cells were
treated for 24 h, G418 was used for 1 month to select
the transfected cells. The short-hairpin RNAsequences
are shown in Additional file 7: Table S2.
Reagents and antibodies
A rabbit anti-human Kir2.1 polyclonal antibody was
purchased from Alomone labs (Jerusalem, Israel),
andpolyclonal anti-MRP1/ABCC1 and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) monoclonal anti-
bodies were purchased from Santa Cruz Inc. (CA,
USA). Horseradish peroxidase (HRP)-labeled goat anti-
rabbit immunoglobulin G (IgG) and goat anti-mouse
IgG were obtained from Santa Cruz Inc. U0126, the MEK
inhibitor, and staurosporine, the PKC inhibitor, were pur-
chased from Selleck Chemicals (Houston, TX, USA). All
three chemotherapeutic drugs, Cisplatin (DDP; Shandong,
China), Etoposide (VP-16; Jiangsu, China) and Adriamycin
(ADM; Jiangsu, China), were obtained from commercial
sources and were dissolved according to the manufac-
turer’s instructions.
RNA isolation, reverse transcription, and quantitative
real-time PCR
Total RNA, including miRNA, was extracted from cell
lines using TRIzol (Invitrogen) or the miRNeasy kit
(Qiagen), according to the manufacturer’s instructions.
For formalin-fixed, paraffin-embedded (FFPE) samples,
total RNA was extracted from ten to fifteen 10-μm-thick
sections usingmiRNeasy FFPE Kit (Qiagen). Total RNA
was reverse transcribed using the PrimeScript RT reagent
Kit (Takala, Dalian, China), andmiRNA sequence-specific
reverse transcription (RT)-PCR for miR-7 and U6 was
performed according to the Hairpin-itTMmiRNAs q-PCR
quantitation kit and the U6 snRNA real-time PCR
normalization kit (GenePharma). Quantitative real-time
PCR was carried out using the MX3005 sequence detec-
tion system (Stratagene) with SYBR Green according to
the manufacturer’s instructions. All primers are listed in
Additional file 7: Table S3. GAPDH and U6 were used as
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internal controls, and fold changes were calculated
through relative quantification (2-△△Ct) [41].
Western blotting assay
For western blotting assays, total proteins were extracted
from cells using RIPA lysis buffer (Sigma-Aldrich) and
quantified using a BCA protein assay kit (Thermo).
Total proteins were separated on 8% SDS–PAGE gels
before being transferred to polyvinylidenedifluoride
membranes (Bio-Rad). After the membranes were
blocked with 5% non-fat milk, they were incubated with
a rabbit anti-human Kir2.1 polyclonal or mouse anti-
human MRP1/ABCC1 polyclonal antibody at 4°C over-
night. GAPDH was used as a protein-loading control.
After washing with Tris-buffered saline solution contain-
ing 0.1% Tween 20 (TBST, Bio-Rad), a peroxidase-linked
secondary goat anti-mouse IgG or goat anti-rabbit IgG
antibody was incubated with the membranes for 1 h at
room temperature. After washing again with TBST, the
protein bands were detected by chemiluminescence. The
intensities of the protein bands were quantified with
the Quantity One software (4.5.0 basic, Bio-Rad).
Immunofluorescence staining
Cells were seeded into 24-well plates for 24 h before be-
ing fixed with paraformaldehyde at 4°C for 30 min. After
being rinsed in PBS, the cells were incubated with 10%
normal calf serum for 30 min to block non-specific IgG
binding sites and then incubated with rabbit anti-human
Kir2.1 monoclonal antibody (Alomone) (1:100 dilution)
at 4°C overnight. A fluorescein isothiocyanate (FITC)-con-
jugated goat anti-rabbit IgGsecondary antibody (1:100 di-
lution) was added, and the cells were incubated for 1.5 h
in the dark at room temperature. All images were cap-
tured using a fluorescence microscope (model Eclipse 660,
Nikon, Japan).
In vitro drug sensitivity assay
Cells were reseeded in 96-well plates at a density of 5 ×
103 per well and treated in medium with ADM, DDP or
VP-16 for 24 h. Cell survival was then analyzed via the
Cell Counting Kit-8 assay (CCK8, Dojindo Molecular
Technologies, Japan) according to the manufacturer’s in-
structions. The range of drug concentrations was based
on earlier studies [42] and was aimed to obtain IC50
values for both highly sensitive and resistant cases. After
incubation with 10 μl of CCK-8 reagent for 4 h,the ab-
sorbance was measuredat 450 nm. The cells incubated
without drugs were set at 100% survival and used to cal-
culate the IC50 of each chemotherapeutic drug. The
assay was carried out in six replicate wells for each sam-
ple, and three parallel experiments were conducted.Flow cytometric analysis
Cells were treated with drugs for 24 h and then collected
for apoptosis and cell cycle analyses. Cell apoptosis as-
says were performed using an Annexin V/propidium
iodide (PI) detection kit (Keygene, Nanjing, China) ac-
cording to the manufacturer’s instructions. For cell cycle
analysis, cells were harvested and fixed in 70% ethanol
overnight at 4°C. After being washed three times in cold
PBS, the cells were incubated with RNase and stained
with PI. Cellquest Pro software was used for apoptosis
analysis and ModFit LT software was used for analysis of
cell cycle. Cells in the quadrant of Annexin V−PI− (lower
left) represent viable cells, cells in the quadrant of
Annexin V−PI+ (upper left) mean necrotic cells, cells in
the quadrant of Annexin V+PI+ (upper right) mean late
apoptotic and dead cells and cells in the quadrant of
Annexin V+PI− (lower right) represent early apoptotic
cells. Usually apoptosis analysis is mainly based on the
percentages of Annexin V+PI− cells. All assays were car-
ried out independently in triplicate.
Immunohistochemical analysis
Paraffin-embedded SCLC samples were sectioned and
mounted on microscopic slides. Polyclonal anti-Kir2.1
and anti-MRP1/ABCC1 antibodies (Alomone Labs Ltd.,
Israel) was used as the primary antibodies. Antigen re-
trieval was performed by microwaving in 10 mmol/L citric
acid buffer at pH 7.2. The samples were incubated first
with the primary antibodies overnight at 4°C, then with
the secondary antibodies for 2 h at room temperature in
the same buffer and finally with abiotinylated secondary
antibody (DAKO, Tokyo, Japan). The bound antibodies
were visualized using the avidinbiotinylated peroxidase
complex and diaminobenzidine tetrachloride methods
(Santa Cruz Biotechnology).
The IHC-stained samples were independently evalu-
ated for Kir2.1 and ABCC1 expressions by two patholo-
gists blinded to the clinical parameters. The staining
intensity was scored as 0 (negative), 1 (weak), 2
(medium) or 3 (strong). The extent of staining was
scored as 0 (0-5%), 1 (6-25%), 2 (26-50%) or 3 (51-
100%), according to the percentages of the positive
stained area in relation to the entire carcinoma-
involved area or the entire normal sample area. The
sum of the intensity and extent scores was used as the
final staining score (0–6). Optimal cut off values were
identified; a final staining score ≤ 1 indicated negative
expression and a final staining score >1 indicated posi-
tive expression.
Luciferase reporter assay
The wildtype and mutated KCNJ23′UTR segments that
were predicted to interact with miR-7 were amplified from
human genomic DNA by PCR and inserted into
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stop codon of (Promega) to develop psiCHECK2-KCNJ2-3′
UTR and psiCHECK2-KCNJ2-mut-3′UTR. Cells in 24-well
plates were transfected with psiCHECK2-KCNJ2-3′UTR,
psiCHECK2-KCNJ2-mut-3′UTR or psiCHECK-2. More-
over, anmiR-7 agomir or antagomiror their corresponding
negative control (NC agomir or NC antagomir) was also
co-transfected into the cells. Luciferase activity was then
assayed 48 h posttransfection using a dual-luciferase re-
porter assay system (Promega).Co-immunoprecipitation
Cells cultured in 10-cm dishes were harvested and
lysed in 500 μl lysis buffer (20 mMTris (pH 7.4), 50
mMNaCl, 1 mM EDTA, 0.5% NP-40, 0.5% SDS, 0.5%
deoxycholate, and protease inhibitors). Then, 500 μg
lysate (1 μg/μl) was precleared with 50 μl protein A-
Sepharose beads (Upstate Biotechnology, NY, USA) for
2 h at 4°C. An appropriate amount of rabbit anti-Kir2.1
antibody (Alomone) or rabbit non-specific IgG (Santa)
was then added and incubated overnight at 4°C. Then,
100 μl preblocked agarose beads was added to the anti-
body/lysate mixture and incubated for another 2 h at
4°C; the beads were then pelleted and washed twice
with lysis buffer. Both the cell lysates without IP and
the immunoprecipitates were eluted in SDS sample
buffer, subjected to SDS-PAGE and analyzed by
immunoblotting.In vivo tumor xenograft model
Six- to eight-week-old female BALB/c nude mice (pur-
chased from the Medical Experimental Animal Center
of Guangdong Province, China) were used for in vivo
assays. The mice were raised under pathogen-free con-
ditions, and all procedures were performed according
to the guidelines of the Association for the Assess-
ment and Accreditation of Laboratory Animal Care
International. Cells were harvested, washed with PBS
and re-suspended in normal culture medium at a con-
centration of 1 × 107 cells/0.1 ml. Cells in RPMI 1640
were subcutaneously inoculated into the legs of nude
mice to establish the tumor model. The tumor volume
was determined three times per week by direct meas-
urement with a sliding caliper and was calculated
using the following equation: V = (4/3) × π × R12× R2,
where R1 is radius 1, R2 is radius 2, and R1 < R2.
Growth curves of the tumors were constructed. After
20 days, 5 mice from each group were sacrificed, and
the tumors were excised and fixed with neutral phos-
phate-buffered formalin. Subsequently, consecutive
tissue sections from the tumors were sliced and then
stained with hematoxylin-eosin.Statistical analysis
All experiments were run in triplicate, and the results
are presented as the mean ± SD. Statistical analyses were
performed using either an analysis of variance (ANOVA)
or Student's t test. The association between Kir2.1or
MRP1/ABCC1 or miR-7expression and clinical features
was analyzed by χ2 test. The relationship between Kir2.1
and MRP1/ABCC1 was explored by χ2 test. Survival
curves were obtained by Kaplain-Meier analysis. The
positive rate of Kir2.1 and MRP1/ABCC1 in normal lung
tissue was compared with that in SCLC tissue by χ2 test.
A difference was considered statistically significant when
the P value was less than 0.05. All statistical analyses
were carried out with SPSS 17.0 software.Additional files
Additional file 1: Figure S1. The semiquantitative analyses of IHC for
Kir2.1 and ABCC1 expression. (A) The final staining scores of IHC in
Figure 1A-D for Kir2.1 and ABCC1 expression in SCLC and normal lung
tissues. (B) The final staining scores of IHC in Figure 6E for Kir2.1
expression.
Additional file 2: Figure S2. Altered expression of KCNJ2/Kir2.1 affects the
cell cycle distribution of SCLC cells after treatment with CDDP.
(A) Representative FACS profiles are shown, on which numbers indicate
percentage of cells in G0/G1, S or G2/M phase. (B) The histographs for cell
cycle distribution of SCLC cells. Data are shown as means ± SD from three
independent experiments. *, P < 0.05; **, P < 0.01 compared to the
corresponding NC cells transfected with pcDNA3.1 empty vector or shNC.
Additional file 3: Figure S3. Altered expression of KCNJ2/Kir2.1 affects
the cell cycle distribution of SCLC cells after treatment with VP-16.
(A) Representative FACS profiles are shown, on which numbers indicate
percentage of cells in G0/G1, S or G2/M phase. (B) The histographs for
cell cycle distribution of SCLC cells. Data are shown as means ± SD from
three independent experiments. *, P < 0.05; **, P < 0.01 compared to the
corresponding NC cells transfected with pcDNA3.1 empty vector or shNC.
Additional file 4: Figure S4. Altered expression of KCNJ2/Kir2.1 affects
cell apoptosis in SCLC cells after treatment with CDDP. (A) Representative
FACS profiles are shown. (B) The histographs for cell apoptosis of SCLC
cells. The results show data from at least three independent experiments.
*, P < 0.05; **, P < 0.01 compared to the corresponding NC cells.
Additional file 5: Figure S5. Altered expression of KCNJ2/Kir2.1 affects
cell apoptosis in SCLC cells after treatment with VP-16. (A) Representative
FACS profiles are shown. (B) The histographs for cell apoptosis of SCLC
cells. The results show data from at least three independent experiments.
*, P < 0.05; **, P < 0.01 compared to the corresponding NC cells.
Additional file 6: Figure S6. Kaplan–Meier analysis of overall survival of
52 patients with SCLC based on miR-7 expression. (P < 0.05).
Additional file 7: Table S1. Univariate analysis of overall survival with
regard to clinicopathological characteristics. Table S2. The sequences of
short hairpin RNA used in vector construction. Table S3. Primers used in
real-time quantitative RT-PCR.Abbreviations
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